X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AMAR REMEDIES Quarterly Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES Quarterly Results   (AMAD)

Here are the latest quarterly results of AMAR REMEDIES. For more details, see the AMAR REMEDIES financial fact sheet and AMAR REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

AMAR REMEDIES Quarterly Results

No. of Mths
Qtr. Ending
3
Sep-11
3
Dec-11
3
Mar-12
3
Jun-12
3
Sep-12
3
Dec-12
3
Mar-13
3
Jun-13
8-Qtr Chart
Click to enlarge
Net Sales Rs m1,5911,6491,6931,8111,5241,6301,310452 
Other income Rs m014525420 
Turnover Rs m1,5911,6631,6981,8131,5291,6341,312452 
Expenses Rs m1,3591,4051,4131,4371,3631,4471,219531 
Gross profit Rs m23224427937316018391-80 
Depreciation Rs m2828284331474721 
Interest Rs m8890104116119124139146 
Profit before tax Rs m1161401522161516-93-247 
Tax Rs m181823643300 
Profit after tax Rs m981221291521213-93-247 
Gross profit margin %14.614.816.520.610.511.26.9-17.7 
Effective tax rate %15.512.915.129.620.018.80.00.0 
Net profit margin %6.27.47.68.40.80.8-7.1-54.6 
Diluted EPS Rs 3.7 4.7 4.9 5.8 0.5 0.5 -3.6 -9.4  
Diluted EPS (TTM) Rs 15.0 16.1 17.3 19.2 15.9 11.7 3.2 -12.0  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

More Consumer Products Company Quarterly Results:   SANOFI INDIA  PANACEA BIOTECH  GSK PHARMA  SUVEN LIFE  NOVARTIS  

Compare AMAR REMEDIES With:   SANOFI INDIA  PANACEA BIOTECH  GSK PHARMA  SUVEN LIFE  NOVARTIS  

Compare AMAR REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Views on news

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

Laurus Labs Ltd (IPO)

Dec 6, 2016

Equitymaster analyses Initial Public Offering (IPO) of Laurus Labs, one of the leading supplier of APIs for ARVs and Hepatitis C.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AMAR REMEDIES

AMAR REMEDIES - HYPERMARCAS COMPARISON

COMPARE AMAR REMEDIES WITH

MARKET STATS